Stay updated on ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial
Sign up to get notified when there's something new on the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page.

Latest updates to the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedFooter update: Revision: v3.3.3 is now displayed and the HHS Vulnerability Disclosure link has been removed. This change does not affect study results or page functionality.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedMinor version update applied: Revision from v3.3.1 to v3.3.2 with no visible changes to page content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check34 days agoChange DetectedAdded detailed numeric outcomes for ORION-3 (mean with 95% CI, ug/L, Day 30/360/720/1440) for LDL-C and PCSK9 in the Inclisiran-only arm, plus expanded participant counts and time-frame descriptions; updated PubMed publication notes to replace older wording.SummaryDifference0.2%

- Check41 days agoChange DetectedDifference0.4%

- Check58 days agoChange DetectedThe ORION-3 results section has been updated to include long-term efficacy and safety data, with LDL-C changes over time and adverse events across treatment arms. This update reflects the four-year open-label extension of ORION-1 and the associated extended follow-up results.SummaryDifference0.0%

- Check65 days agoChange DetectedNo significant additions or deletions were detected on the page; the study results information and layout appear unchanged.SummaryDifference0.0%

Stay in the know with updates to ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ORION-3 Extension Trial: Inclisiran in Cardiovascular Disease Clinical Trial page.